Clodronic acid
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.031.090 |
| Chemical and physical data | |
| Formula | CH4Cl2O6P2 |
| Molar mass | 244.88 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Clodronic acid (INN) or clodronate disodium (Na2CH2Cl2O6P2) (USAN) is a first generation (non-nitrogenous) bisphosphonate. It is an anti-osteoporotic drug approved for the prevention and treatment of osteoporosis in post-menopausal women and men to reduce vertebral fractures, hyperparathyroidism, hypercalcemia in malignancy, multiple myeloma and fracture related pain because of its anti-inflammatory effects shown as a reduction in inflammatory markers like IL-1β, IL-6, and TNF-α.[1]
Medical uses
[edit]A study comparing the analgesic effect of clodronic acid versus acetaminophen in osteoporotic vertebral fractures showed that clodronic acid provided more analgesia than 3 grams/day of acetaminophen.[2]
Clodronic acid is also used in experimental medicine to selectively deplete macrophages.
Clodronic acid is approved for human use in Canada and Australia, the United Kingdom, where it is marketed as Bonefos, Loron, Clodron and in Italy as Clasteon, Difosfonal, Osteostab and several generics. In other countries is prescribed as a bone resorption inhibitor and antihypercalcemic agent. It is not approved for use in the United States, because it has too many adverse effects.
Veterinary uses
[edit]Clodronic acid is approved for use in horses under the trade name Osphos, for treatment of bone resorptive processes of navicular syndrome. It is given by intramuscular injection at one point in time, with the total dose divided into 2-3 sites on the horse. Clinical effects (e.g. improvement of lameness) after a single treatment can be seen up to 6 months post-treatment.
Adverse effects
[edit]Clodronic acid has been shown to have several adverse effects. These include:[3]
- Signs of discomfort, agitation, or colic, usually within 2 hours of treatment.
- Head shaking
- Lip licking
- Renal failure
References
[edit]- ^ Pennanen N, Lapinjoki S, Urtti A, Mönkkönen J (June 1995). "Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro". Pharmaceutical Research. 12 (6): 916–22. doi:10.1023/A:1016281608773. PMID 7667201. S2CID 46332840.
- ^ Rovetta G, Monteforte P, Balestra V (2000). "Intravenous clodronate for acute pain induced by osteoporotic vertebral fracture". Drugs Under Experimental and Clinical Research. 26 (1): 25–30. PMID 10761534.
- ^ U.S. Food and Drug Administration. "FDA Provides Equine Veterinarians with Important Information about TILDREN and OSPHOS for Navicular Syndrome in Horses". Food and Drug Administration. Retrieved 3 January 2015.
Drugs for treatment of bone diseases (M05) | |
|---|---|
| Bisphosphonates | |
| Bone morphogenetic proteins | |
| Other |
|
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
